iCAD exhibits ProFound AI™ platform for DBT at the EUSOBI in Budapest
Category: #health  By Mateen Dalal  Date: 2019-10-03
  • share
  • Twitter
  • Facebook
  • LinkedIn

iCAD exhibits ProFound AI™ platform for DBT at the EUSOBI in Budapest

Breast cancer is one of the most prominent cancer types that can occur in women. Though treatment options depend on the stage of the disease, it can be addressed successfully if diagnosed and treated early. Various medical and pharmaceutical firms across the world are increasingly working towards finding more effective solutions as well as spreading awareness about breast cancer protection and prevention.   

iCAD, a renowned medical technology leader offering innovative cancer diagnostics and therapy solutions, reportedly announced that it would be showcasing the ProFound AI™ platform, which would also include its ProFound AI™ for DBT (Digital Breast Tomosynthesis) as well as ProFound AI™ for 2D Mammography in its iCAD exhibition booth, at the upcoming European Society of Breast Imaging (EUSOBI) conference from October 3 to October 5, 2019 at Budapest, Hungary.

ProFound AI made for DBT received the CE marking earlier in March 2018 and was approved by FDA in December 2018. Meanwhile, the ProFound AI for 2D Mammography received its CE marking recently in July and then it was launched in Europe.

ProFound AI is a high-performance workflow solution designed on the newest deep-learning AI technology. according to a recent study posted in the Radiology: Artificial Intelligence, iCAD’s ProFound AI for DBT was discovered to enhance rates of breast cancer detection by 8%, decrease unnecessary recall rates approximately by 7.2%, and cut down on reading time for a radiologist by 52.7%.

The software accurately and rapidly analyzes every tomosynthesis image, identifying both malignant soft tissue calcifications and densities with accuracy. It offers radiologists a Certainty of Finding lesion and Case Scores, that further assists in prioritizing caseloads and clinical decision-making.

Featuring the latest deep-learning AI, the ProFound AI platform further allows for continuously enhanced performance through ongoing updates.

CEO and Chairman of iCAD, Michael Klein stated that the ProFound AI platform was trained using one of the biggest available datasets and it is the industry’s first as well as its only software solution for DBT which is clinically proven to boost specificity and sensitivity, while reducing the required time for reading for radiologists.

Klein added that ProFound AI is increasingly being adopted across Europe, however, now as ProFound AI for 2D Mammography is launched, clinical benefits of ProFound AI are being recognized by a greater number of radiologists; discovering that it offers clinical benefits to their departments as well as their patients.

 

 

 

 

 

Source credit: https://www.globenewswire.com/news-release/2019/10/01/1923007/0/en/iCAD-Showcases-ProFound-AI-Platform-at-European-Society-of-Breast-Imaging-Annual-Scientific-Meeting-in-Budapest.html

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More

More News By Mateen Dalal

Airbus cuts back production of jets amid rising COVID-19 concerns
Airbus cuts back production of jets amid rising COVID-19 concerns
By Mateen Dalal

Aircraft manufacturer Airbus is reportedly set to reduce jet plane production by a third. This decision has been taken considering the possibility of further impact on the global aviation industry by the coronavirus epidemic, even after the easing of...

AIVITA declares updates for AV-GMB-1 clinical trial in GBM patients
AIVITA declares updates for AV-GMB-1 clinical trial in GBM patients
By Mateen Dalal

AIVITA Biomedical, Inc., a biotech firm developing innovative cell therapies, has recently announced updates to the survival data after the year-end analysis of the ongoing AV-GBM-1 Phase 2 clinical trial in newly diagnosed glioblastoma (GBM) patient...

Lufthansa to shut down Germanwings & de-commission over 40 aircrafts
Lufthansa to shut down Germanwings & de-commission over 40 aircrafts
By Mateen Dalal

Lufthansa, the flag carrier and largest German airline, is reportedly shutting down its Germanwings, a low-cost airline, due to the rising impact of coronavirus on the business. The airline is also planning to de-commission over 40 aircrafts due to t...